Merck Re-enters Flu Vaccine Business: Seals Six-year Afluria Marketing Deal With CSL
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal with long-time Australian partner could add up to $100 million to Merck's business in the 2010/2011 flu season, analyst says.